Trump Pharmaceutical Tariffs Target Imported Drugs

Trump pharmaceutical tariffs aim to boost U.S. production and pricing agreements by imposing levies on imports under Section 232, the White House said in a proclamation on April 2, 2026. The move could reshape drugmakers' supply chains and capital plans.

Tariff Structure, Exemptions, and Implementation Timeline

The presidential proclamation imposes a 100% ad valorem duty on patented pharmaceuticals and active pharmaceutical ingredients (APIs) listed in Annex I. The tariffs are calculated as a percentage of import value rather than per unit. The action relies on Section 232 of the Trade Expansion Act of 1962 and Section 604 of the Trade Act of 1974 to embed the measures in U.S. tariff law. The Commerce Department’s investigation found that 53% of patented drugs distributed domestically are produced abroad, while only 15% of patented APIs by volume are made in the U.S.

The proclamation sets a 120-day implementation window for large companies and 180 days for smaller ones. It directs the Commerce Department and Health and Human Services (HHS) to report negotiation progress within 90 days, around July 1, 2026. Annex II references existing trade commitments with the European Union, Japan, South Korea, Switzerland/Liechtenstein, and the United Kingdom, while Annex IV lists products currently at zero tariff.

The tariff rates vary by category and trade partner. Firms that commit to pricing and domestic production can qualify for a zero-duty carve-out through January 20, 2029. Approved domestic-production plans face a 20% rate that will escalate to the full tariff on April 2, 2030. Products from the EU, Japan, South Korea, and Switzerland/Liechtenstein carry a 15% rate. The United Kingdom faces a 10% rate, subject to reduction under a separate pharmaceutical agreement reached in principle on December 1, 2025. Orphan drugs and certain specialty therapies, including nuclear medicines and fertility treatments, are exempt. Generic drugs, including biosimilars, are exempt for now but will be reassessed in about one year.

Exemptions, Deals, and Investment Commitments

The White House fact sheet states the tariffs have already prompted roughly $400 billion in new domestic-investment commitments from U.S. and foreign pharmaceutical companies during the administration. At least 13 major drugmakers—including Pfizer, Merck, Bristol Myers Squibb, and AstraZeneca—have pre-negotiated confidential most-favored-nation (MFN) pricing and onshoring agreements with the White House. These deals secure full tariff exemptions and require firms to offer medicines to Medicaid at MFN prices, launch new drugs in the U.S. at those prices, and build U.S. manufacturing capacity.

Other manufacturers without prior arrangements can negotiate similar agreements with the Commerce Department to reduce tariffs for the remainder of the administration. The fact sheet outlines monitoring and enforcement tools, including external audits and potential tariff increases on past and future imports.

A senior administration official said the expectation is that all major patented-pharmaceutical firms will establish production facilities in the U.S. The fact sheet emphasized the national-security rationale: "President Trump imposed these tariffs following an extensive investigation conducted by the Secretary of Commerce under Section 232 of the Trade Expansion Act of 1962, as amended, to determine the effects on national security of imports of pharmaceuticals, pharmaceutical ingredients, and related products."

The immediate effect favors companies with existing agreements while accelerating decision timetables for others weighing capital investment against pricing concessions. The extent to which firms build U.S. capacity or accept the administration’s pricing terms will determine whether the tariffs produce lasting changes in supply chains and industry pricing.

Quotes

"President Trump imposed these tariffs following an extensive investigation conducted by the Secretary of Commerce under Section 232 of the Trade Expansion Act of 1962, as amended, to determine the effects on national security of imports of pharmaceuticals, pharmaceutical ingredients, and related products." — White House Fact Sheet